<p>TScan Therapeutics（納斯達克代碼：TCRX - 獲取免費報告）於週二發佈了季度財報。該公司報告的每股收益（EPS）為（$0.28），超出分析師一致預期的（$0.35）$0.07，FiscalAI 報道。該季度的收入為 251 萬美元，而一致預期為 198 萬美元。TScan Therapeutics 的股本回報率為負的 63.33%，淨利潤率為負的 1,964.88%。</p>
<p>獲取 <strong>TScan Therapeutics</strong> 的提醒：</p>
<h2>TScan Therapeutics 股票表現</h2>
<p>週三午盤交易中，TCRX 股票下跌$0.04，報$1.18。該公司的交易量為 414,920 股，而其平均交易量為 507,574 股。該公司的市值為 6697 萬美元，市盈率為-1.08，貝塔係數為 1.00。公司的債務與股本比率為 0.18，速動比率為 7.06，流動比率為 7.06。TScan Therapeutics 的 12 個月低點為$1.02，12 個月高點為$5.56。該股票的 50 日移動平均價格為$1.88，200 日移動平均價格為$1.71。</p>
<h2>華爾街分析師預測增長</h2>
<p>一些研究分析師最近對該公司進行了評估。Wedbush 在 8 月 12 日的報告中重申了 “跑贏大盤” 的評級，並對 TScan Therapeutics 的股票設定了$7.00 的目標價。Weiss Ratings 在 10 月 8 日的報告中重申了對 TScan Therapeutics 股票的 “賣出（d-）” 評級。BTIG Research 在 11 月 4 日的研究報告中將 TScan Therapeutics 的股票評級從 “買入” 下調至 “中性”。最後，Needham &amp; Company LLC 在 11 月 4 日的研究報告中將 TScan Therapeutics 的股票目標價從$9.00 下調至$6.00，並對該股票設定了 “買入” 評級。五位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為$7.20。</p>
<p><strong>查看我們關於 TCRX 的最新研究報告</strong></p>
<h2>對 TScan Therapeutics 的對沖基金看法</h2>
<p>機構投資者最近買入和賣出了該公司的股票。Vanguard Group Inc.在第三季度將其在 TScan Therapeutics 的持股增加了 7.8%。Vanguard Group Inc.現在擁有 2317916 股該公司的股票，價值 421.9 萬美元，此前在上個季度又購買了 168540 股。Militia Capital Partners LP 在第二季度購買了 TScan Therapeutics 的新股份，價值約為 137,000 美元。Bridgeway Capital Management LLC 在第二季度將其在 TScan Therapeutics 的持股增加了 35.7%。Bridgeway Capital Management LLC 現在擁有 153700 股該公司的股票，價值 223,000 美元，此前在此期間又收購了 40400 股。美國銀行在第二季度將其在 TScan Therapeutics 的持股增加了 28.0%。美國銀行現在擁有 217967 股該公司的股票，價值 316,000 美元，此前在此期間又購買了 47617 股。最後，Jane Street Group LLC 在第二季度購買了 TScan Therapeutics 的新股份，價值 309,000 美元。對沖基金和其他機構投資者持有該公司 82.83% 的股票。</p>
<h2>關於 TScan Therapeutics</h2>
<p>（獲取免費報告）</p>
<p>TScan Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發 T 細胞受體工程 T 細胞（TCR-T）療法，用於治療美國癌症患者。該公司的主要產品候選包括 TSC-100 和 TSC-101，目前正在進行針對血液惡性腫瘤患者的 I 期臨牀試驗，以消除殘餘疾病並防止同種異體造血幹細胞移植後的復發。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 TScan Therapeutics</li>
<li>價值投資：2022 年是個好策略嗎？提示：永遠</li>
<li>Papa John's 27 億美元收購提議：未開發價值的價格</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>高通是上漲 40% 還是下跌 20%？兩種逆向觀點</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>Guardian Pharmacy 股票因第三季度強勁表現和樂觀預測而上漲</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 TScan Therapeutics 嗎？</h2>
<p>在你考慮 TScan Therapeutics 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 TScan Therapeutics 並不在名單上。</p>
<p>雖然 TScan Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

TCRX

<p>TScan Therapeutics 報告了季度收益，每股收益超出預期 0.07 美元。該公司發佈的每股收益為（0.28）美元，超過了市場共識的（0.35）美元。收入為 251 萬美元，高於預期的 198 萬美元。儘管股本回報率和淨利潤率為負，分析師的評級卻各不相同，整體評級為適度買入，平均目標價為 7.20 美元。機構投資者持有 82.83% 的股份。TScan 開發用於癌症治療的 TCR-T 療法</p>

<p>TScan Therapeutics (NASDAQ:TCRX - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.07, FiscalAI reports. The business had revenue of $2.51 million during the quarter, compared to the consensus estimate of $1.98 million. TScan Therapeutics had a negative return on equity of 63.33% and a negative net margin of 1,964.88%.</p>
<div class="lb-trans"><p>TScan Therapeutics（納斯達克代碼：TCRX - 獲取免費報告）於週二發佈了季度財報。該公司報告的每股收益（EPS）為（$0.28），超出分析師一致預期的（$0.35）$0.07，FiscalAI 報道。該季度的收入為 251 萬美元，而一致預期為 198 萬美元。TScan Therapeutics 的股本回報率為負的 63.33%，淨利潤率為負的 1,964.88%。</p>
</div><p>Get <strong>TScan Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>TScan Therapeutics</strong> 的提醒：</p>
</div><h2>TScan Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>TScan Therapeutics 股票表現</h2>
</div><p>TCRX stock traded down $0.04 during mid-day trading on Wednesday, hitting $1.18. The company had a trading volume of 414,920 shares, compared to its average volume of 507,574. The firm has a market cap of $66.97 million, a PE ratio of -1.08 and a beta of 1.00. The company has a debt-to-equity ratio of 0.18, a quick ratio of 7.06 and a current ratio of 7.06. TScan Therapeutics has a 12 month low of $1.02 and a 12 month high of $5.56. The stock's fifty day moving average price is $1.88 and its two-hundred day moving average price is $1.71.</p>
<div class="lb-trans"><p>週三午盤交易中，TCRX 股票下跌$0.04，報$1.18。該公司的交易量為 414,920 股，而其平均交易量為 507,574 股。該公司的市值為 6697 萬美元，市盈率為-1.08，貝塔係數為 1.00。公司的債務與股本比率為 0.18，速動比率為 7.06，流動比率為 7.06。TScan Therapeutics 的 12 個月低點為$1.02，12 個月高點為$5.56。該股票的 50 日移動平均價格為$1.88，200 日移動平均價格為$1.71。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>A number of research analysts have recently weighed in on the company. Wedbush restated an &#34;outperform&#34; rating and issued a $7.00 target price on shares of TScan Therapeutics in a report on Tuesday, August 12th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. BTIG Research lowered shares of TScan Therapeutics from a &#34;buy&#34; rating to a &#34;neutral&#34; rating in a research note on Tuesday, November 4th. Finally, Needham &amp; Company LLC dropped their price target on shares of TScan Therapeutics from $9.00 to $6.00 and set a &#34;buy&#34; rating on the stock in a research report on Tuesday, November 4th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $7.20.</p>
<div class="lb-trans"><p>一些研究分析師最近對該公司進行了評估。Wedbush 在 8 月 12 日的報告中重申了 “跑贏大盤” 的評級，並對 TScan Therapeutics 的股票設定了$7.00 的目標價。Weiss Ratings 在 10 月 8 日的報告中重申了對 TScan Therapeutics 股票的 “賣出（d-）” 評級。BTIG Research 在 11 月 4 日的研究報告中將 TScan Therapeutics 的股票評級從 “買入” 下調至 “中性”。最後，Needham &amp; Company LLC 在 11 月 4 日的研究報告中將 TScan Therapeutics 的股票目標價從$9.00 下調至$6.00，並對該股票設定了 “買入” 評級。五位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司的平均評級為 “適度買入”，平均目標價為$7.20。</p>
</div><p><strong>Check Out Our Latest Research Report on TCRX</strong></p>
<div class="lb-trans"><p><strong>查看我們關於 TCRX 的最新研究報告</strong></p>
</div><h2>Hedge Funds Weigh In On TScan Therapeutics</h2>
<div class="lb-trans"><h2>對 TScan Therapeutics 的對沖基金看法</h2>
</div><p>Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. lifted its position in shares of TScan Therapeutics by 7.8% during the 3rd quarter. Vanguard Group Inc. now owns 2,317,916 shares of the company's stock valued at $4,219,000 after buying an additional 168,540 shares during the last quarter. Militia Capital Partners LP purchased a new stake in TScan Therapeutics in the 2nd quarter worth about $137,000. Bridgeway Capital Management LLC raised its stake in TScan Therapeutics by 35.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 153,700 shares of the company's stock valued at $223,000 after acquiring an additional 40,400 shares during the period. Bank of America Corp DE raised its position in shares of TScan Therapeutics by 28.0% in the second quarter. Bank of America Corp DE now owns 217,967 shares of the company's stock valued at $316,000 after purchasing an additional 47,617 shares during the period. Finally, Jane Street Group LLC bought a new position in shares of TScan Therapeutics in the second quarter worth $309,000. Hedge funds and other institutional investors own 82.83% of the company's stock.</p>
<div class="lb-trans"><p>機構投資者最近買入和賣出了該公司的股票。Vanguard Group Inc.在第三季度將其在 TScan Therapeutics 的持股增加了 7.8%。Vanguard Group Inc.現在擁有 2317916 股該公司的股票，價值 421.9 萬美元，此前在上個季度又購買了 168540 股。Militia Capital Partners LP 在第二季度購買了 TScan Therapeutics 的新股份，價值約為 137,000 美元。Bridgeway Capital Management LLC 在第二季度將其在 TScan Therapeutics 的持股增加了 35.7%。Bridgeway Capital Management LLC 現在擁有 153700 股該公司的股票，價值 223,000 美元，此前在此期間又收購了 40400 股。美國銀行在第二季度將其在 TScan Therapeutics 的持股增加了 28.0%。美國銀行現在擁有 217967 股該公司的股票，價值 316,000 美元，此前在此期間又購買了 47617 股。最後，Jane Street Group LLC 在第二季度購買了 TScan Therapeutics 的新股份，價值 309,000 美元。對沖基金和其他機構投資者持有該公司 82.83% 的股票。</p>
</div><h2>About TScan Therapeutics</h2>
<div class="lb-trans"><h2>關於 TScan Therapeutics</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.</p>
<div class="lb-trans"><p>TScan Therapeutics, Inc.是一家臨牀階段的生物製藥公司，開發 T 細胞受體工程 T 細胞（TCR-T）療法，用於治療美國癌症患者。該公司的主要產品候選包括 TSC-100 和 TSC-101，目前正在進行針對血液惡性腫瘤患者的 I 期臨牀試驗，以消除殘餘疾病並防止同種異體造血幹細胞移植後的復發。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than TScan Therapeutics</li>
<li>Value Investing: Is it a Good Strategy in 2022? Hint: Always</li>
<li>Papa John's $2.7 Billion Takeover Bid: A Price on Untapped Value</li>
<li>Airline Stocks - Top Airline Stocks to Buy Now</li>
<li>Is Qualcomm Up 40% or Down 20%? 2 Contrarian Takes</li>
<li>Stock Analyst Ratings and Canadian Analyst Ratings</li>
<li>Guardian Pharmacy Stock Pops on Q3 Strength and Upbeat Forecast</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 TScan Therapeutics</li>
<li>價值投資：2022 年是個好策略嗎？提示：永遠</li>
<li>Papa John's 27 億美元收購提議：未開發價值的價格</li>
<li>航空公司股票 - 現在值得購買的頂級航空公司股票</li>
<li>高通是上漲 40% 還是下跌 20%？兩種逆向觀點</li>
<li>股票分析師評級和加拿大分析師評級</li>
<li>Guardian Pharmacy 股票因第三季度強勁表現和樂觀預測而上漲</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VENSWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=TCRX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TScan Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 TScan Therapeutics 嗎？</h2>
</div><p>Before you consider TScan Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 TScan Therapeutics 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TScan Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 TScan Therapeutics 並不在名單上。</p>
</div><p>While TScan Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 TScan Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

TScan Therapeutics（納斯達克股票代碼：TCRX）公佈季度財報，每股收益比預期高出 0.07 美元